Status:
COMPLETED
First-trimester Prediction of Preeclampsia
Lead Sponsor:
CHU de Quebec-Universite Laval
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Laval University
Conditions:
Preeclampsia
Severe Preeclampsia
Eligibility:
FEMALE
18+ years
Brief Summary
Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death. Several measures are used or under investigation ...
Detailed Description
Background: Preeclampsia (PE) is a placenta-mediated pregnancy complication related to adverse maternal and neonatal outcomes, including intra-uterine growth restriction (IUGR) and perinatal death. A ...
Eligibility Criteria
Inclusion
- gestational age between 11 3/7 and 13 6/7 weeks;
- nulliparous women (no previous delivery ≥ 20 weeks).
Exclusion
- pregnant women \<18 years old at recruitment;
- multiple pregnancies;
- fetal congenital malformation;
- positive for HIV or hepatitis C or hepatitis B;
- negative fetal heart at recruitment;
- women planning a delivery outside the participating hospitals;
- women not able to provide an informed consent to the study.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
7554 Patients enrolled
Trial Details
Trial ID
NCT02189148
Start Date
November 1 2014
End Date
March 1 2018
Last Update
July 23 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
South Alberta Maternal Fetal Medicine Centre, University of Calgary
Calgary, Alberta, Canada
2
Sinai Health System, Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
3
CHU Ste-Justine
Montreal, Quebec, Canada, H3T 1C5
4
CHU de Québec
Québec, Quebec, Canada, G1V 4G2